Takaaki Sawada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Takaaki Sawada has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Jun Kido
Department of Pediatrics, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
3 shared publications - Kimitoshi Nakamura
Department of Pediatrics, Kumamoto University Hospital, Kumamoto, Japan
3 shared publications Jun Kido
Department of Pediatrics, Kumamoto University Hospital, Kumamoto 860-8556, Japan; Department of Pediatrics, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan
2 shared publicationsKeishin Sugawara
Department of Pediatrics, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan
2 shared publications- Keishin Sugawara
Department of Pediatrics, Faculty of Life Sciences, Kumamoto University , Kumamoto 860-8556
2 shared publications Kimitoshi Nakamura
Department of Pediatrics, Kumamoto University Hospital, Kumamoto 860-8556, Japan; Department of Pediatrics, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan
2 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 149 (1-2) , 110210
Implementation of a dried blood spot-based Newborn screening program for adenosine deaminase deficiency: An initial experience in Japan
- 13 July 2026
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 149 (1-2) , 110210
Open AccessImplementation of a dried blood spot-based Newborn screening program for adenosine deaminase deficiency: An initial experience in Japan
- Open Access
- 2 September 2025
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 84 (1) , 549-560
T-Cell Receptor Excision Circle/Kappa-Deleting Recombination Excision Circle-Based Newborn Screening Program for Severe Combined Immunodeficiency in Kumamoto, Japan
Severe combined immunodeficiency (SCID) is a life-threatening hereditary disorder that requires early diagnosis and intervention. Therefore, this study aimed to evaluate the utility of T-cell receptor excision circle (TREC) and kappa-deleting recombination excision circle (KREC) measurements in newborn screening (NBS) for SCID and other primary immunodeficiencies in Kumamoto Prefecture, Japan. In a TREC-based NBS program (February 2019–March 2022, N = 43,658), six newborns (0.014%) underwent immunological testing, and three (0.007%) were diagnosed with T-cell lymphopenia. In a subsequent combined TREC/KREC-based NBS program (April 2022–March 2023, N = 12,335), eight newborns (0.065%) required further testing, and one (0.008%) was diagnosed with X-linked agammaglobulinemia. Decreased KREC levels were observed in two newborns exposed to maternal azathioprine (AZP). The TREC levels tended to be lower in more premature infants, whereas the KREC levels showed no clear correlation with gestational age (GA). Both the TREC and KREC levels were reduced in infants with low birth weights (BWs). These findings indicate that the combined TREC/KREC-based NBS program is an effective approach for detecting T- and B-cell immunodeficiencies. However, clinical factors such as maternal AZP exposure, low GA, and low BW may affect TREC and/or KREC levels, necessitating careful interpretation of results from dried blood spot samples.
- 2 September 2025
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 84 (1) , 549-560
Open AccessT-Cell Receptor Excision Circle/Kappa-Deleting Recombination Excision Circle-Based Newborn Screening Program for Severe Combined Immunodeficiency in Kumamoto, Japan
Severe combined immunodeficiency (SCID) is a life-threatening hereditary disorder that requires early diagnosis and intervention. Therefore, this study aimed to evaluate the utility of T-cell receptor excision circle (TREC) and kappa-deleting recombination excision circle (KREC) measurements in newborn screening (NBS) for SCID and other primary immunodeficiencies in Kumamoto Prefecture, Japan. In a TREC-based NBS program (February 2019–March 2022, N = 43,658), six newborns (0.014%) underwent immunological testing, and three (0.007%) were diagnosed with T-cell lymphopenia. In a subsequent combined TREC/KREC-based NBS program (April 2022–March 2023, N = 12,335), eight newborns (0.065%) required further testing, and one (0.008%) was diagnosed with X-linked agammaglobulinemia. Decreased KREC levels were observed in two newborns exposed to maternal azathioprine (AZP). The TREC levels tended to be lower in more premature infants, whereas the KREC levels showed no clear correlation with gestational age (GA). Both the TREC and KREC levels were reduced in infants with low birth weights (BWs). These findings indicate that the combined TREC/KREC-based NBS program is an effective approach for detecting T- and B-cell immunodeficiencies. However, clinical factors such as maternal AZP exposure, low GA, and low BW may affect TREC and/or KREC levels, necessitating careful interpretation of results from dried blood spot samples.
- Open Access
- 28 December 2024
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (3) , ziae172
Newborn screening for hypophosphatasia: development of a high-throughput tissue nonspecific alkaline phosphatase activity assay using dried blood spots
Hypophosphatasia (HPP) is an inherited metabolic disease caused by deficiency of tissue nonspecific alkaline phosphatase (TNAP) caused by pathogenic variants of the ALPL gene (MIM 171760). The clinical manifestations of HPP vary, ranging from a lethal perinatal-onset type to a moderate late-onset type presenting with nonspecific symptoms, such as arthropathy and musculoskeletal pain. HPP is characterized by low TNAP activity and defective bone mineralization, leading to bone deformity and skeletal abnormalities. Moreover, this disease can cause systemic complications, such as muscle weakness, seizures, pain, and respiratory failure, leading to premature death in infants. This study aimed to evaluate whether measuring TNAP activity in dried blood spots (DBSs) can identify patients with HPP. We developed an assay to assess TNAP activity using DBSs and screened 45 632 newborns born between February 2019 and March 2022 in Kumamoto Prefecture in Japan for HPP. We detected a single heterozygous variant of the ALPL gene in 5 newborns. During the clinical course follow-up, one newborn presented with HPP-related clinical manifestations. This is the first study on newborn screening (NBS) for HPP worldwide. NBS for HPP using DBSs may be practical and beneficial, as it is a high-throughput method. Moreover, the DBSs used for the TNAP assay are the same as those used for public-funded NBS worldwide. In the future, this system may be implemented as standard NBS for HPP.
- 28 December 2024
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (3) , ziae172
Open AccessNewborn screening for hypophosphatasia: development of a high-throughput tissue nonspecific alkaline phosphatase activity assay using dried blood spots
Hypophosphatasia (HPP) is an inherited metabolic disease caused by deficiency of tissue nonspecific alkaline phosphatase (TNAP) caused by pathogenic variants of the ALPL gene (MIM 171760). The clinical manifestations of HPP vary, ranging from a lethal perinatal-onset type to a moderate late-onset type presenting with nonspecific symptoms, such as arthropathy and musculoskeletal pain. HPP is characterized by low TNAP activity and defective bone mineralization, leading to bone deformity and skeletal abnormalities. Moreover, this disease can cause systemic complications, such as muscle weakness, seizures, pain, and respiratory failure, leading to premature death in infants. This study aimed to evaluate whether measuring TNAP activity in dried blood spots (DBSs) can identify patients with HPP. We developed an assay to assess TNAP activity using DBSs and screened 45 632 newborns born between February 2019 and March 2022 in Kumamoto Prefecture in Japan for HPP. We detected a single heterozygous variant of the ALPL gene in 5 newborns. During the clinical course follow-up, one newborn presented with HPP-related clinical manifestations. This is the first study on newborn screening (NBS) for HPP worldwide. NBS for HPP using DBSs may be practical and beneficial, as it is a high-throughput method. Moreover, the DBSs used for the TNAP assay are the same as those used for public-funded NBS worldwide. In the future, this system may be implemented as standard NBS for HPP.
- Open Access
- 27 September 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (10) , 1779
High-Risk Screening for Fabry Disease: A Nationwide Study in Japan and Literature Review
Fabry disease (FD) is an X-linked inherited disorder caused by mutations in the GLA gene, which encodes the lysosomal enzyme α-galactosidase A (α-Gal A). FD detection in patients at an early stage is essential to achieve sufficient treatment effects, and high-risk screening may be effective. Here, we performed high-risk screening for FD in Japan and showed that peripheral neurological manifestations are important in young patients with FD. Moreover, we reviewed the literature on high-risk screening in patients with renal, cardiac, and central neurological manifestations. Based on the results of this study and review of research abroad, we believe that FD can be detected more effectively by targeting individuals based on age. In recent years, the methods for high-risk screening have been ameliorated, and high-risk screening studies using GLA next-generation sequencing have been conducted. Considering the cost-effectiveness of screening, GLA sequencing should be performed in individuals with reduced α-Gal A activity and females with certain FD manifestations and/or a family history of FD. The findings suggest that family analysis would likely detect FD patients, although GLA sequencing of asymptomatic family members requires adequate genetic counseling.
- 27 September 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (10) , 1779
Open AccessHigh-Risk Screening for Fabry Disease: A Nationwide Study in Japan and Literature Review
Fabry disease (FD) is an X-linked inherited disorder caused by mutations in the GLA gene, which encodes the lysosomal enzyme α-galactosidase A (α-Gal A). FD detection in patients at an early stage is essential to achieve sufficient treatment effects, and high-risk screening may be effective. Here, we performed high-risk screening for FD in Japan and showed that peripheral neurological manifestations are important in young patients with FD. Moreover, we reviewed the literature on high-risk screening in patients with renal, cardiac, and central neurological manifestations. Based on the results of this study and review of research abroad, we believe that FD can be detected more effectively by targeting individuals based on age. In recent years, the methods for high-risk screening have been ameliorated, and high-risk screening studies using GLA next-generation sequencing have been conducted. Considering the cost-effectiveness of screening, GLA sequencing should be performed in individuals with reduced α-Gal A activity and females with certain FD manifestations and/or a family history of FD. The findings suggest that family analysis would likely detect FD patients, although GLA sequencing of asymptomatic family members requires adequate genetic counseling.
- Open Access
- 5 April 2020
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (2) , 31
Newborn Screening for Pompe Disease
Glycogen storage disease type II (also known as Pompe disease (PD)) is an autosomal recessive disorder caused by defects in α-glucosidase (AαGlu), resulting in lysosomal glycogen accumulation in skeletal and heart muscles. Accumulation and tissue damage rates depend on residual enzyme activity. Enzyme replacement therapy (ERT) should be started before symptoms are apparent in order to achieve optimal outcomes. Early initiation of ERT in infantile-onset PD improves survival, reduces the need for ventilation, results in earlier independent walking, and enhances patient quality of life. Newborn screening (NBS) is the optimal approach for early diagnosis and treatment of PD. In NBS for PD, measurement of AαGlu enzyme activity in dried blood spots (DBSs) is conducted using fluorometry, tandem mass spectrometry, or digital microfluidic fluorometry. The presence of pseudodeficiency alleles, which are frequent in Asian populations, interferes with NBS for PD, and current NBS systems cannot discriminate between pseudodeficiency and cases with PD or potential PD. The combination of GAA gene analysis with NBS is essential for definitive diagnoses of PD. In this review, we introduce our experiences and discuss NBS programs for PD implemented in various countries.
- 5 April 2020
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (2) , 31
Open AccessNewborn Screening for Pompe Disease
Glycogen storage disease type II (also known as Pompe disease (PD)) is an autosomal recessive disorder caused by defects in α-glucosidase (AαGlu), resulting in lysosomal glycogen accumulation in skeletal and heart muscles. Accumulation and tissue damage rates depend on residual enzyme activity. Enzyme replacement therapy (ERT) should be started before symptoms are apparent in order to achieve optimal outcomes. Early initiation of ERT in infantile-onset PD improves survival, reduces the need for ventilation, results in earlier independent walking, and enhances patient quality of life. Newborn screening (NBS) is the optimal approach for early diagnosis and treatment of PD. In NBS for PD, measurement of AαGlu enzyme activity in dried blood spots (DBSs) is conducted using fluorometry, tandem mass spectrometry, or digital microfluidic fluorometry. The presence of pseudodeficiency alleles, which are frequent in Asian populations, interferes with NBS for PD, and current NBS systems cannot discriminate between pseudodeficiency and cases with PD or potential PD. The combination of GAA gene analysis with NBS is essential for definitive diagnoses of PD. In this review, we introduce our experiences and discuss NBS programs for PD implemented in various countries.